霉酚酸酯联合金水宝治疗HBV-DNA阳性肾小球疾病的疗效

The Therapeutic Efficacy of Mycophenolate Mofetil Combined with Jinshuibao in the Renal Glomerular Disease Patients with Positive HBV-DNA

目的:观察霉酚酸酯(mycophenolate mofetil,MMF)和冬虫夏草人工制剂(金水宝)联合治疗HBV-DNA阳性肾小球疾病的有效性,安全性。方法:对10例HBV-DNA阳性的肾小球疾病患者用MMF和金水宝治疗。在治疗前及治疗6个月后测定肝肾功能、血白细胞、血红蛋白、24 h尿蛋白定量、HBV-DNA滴度及肾组织活检。结果:治疗后尿蛋白,血肌酐,HBV-DNA均明显下降,差异有显著性(P<0.05),而血白细胞、血红蛋白、谷丙转氨酶,治疗前后无明显变化(P>0.05)。结论:霉酚酸酯和金水宝联合治疗HBV-DNA阳性的肾小球疾病为一种较安全有效的方法,但尚需扩大临床研究。

Objective：To observe the therapeutic efficacy and safety of MMF combined with Jinshuibao in renal glomerular disease patients with HBV-DNA positive.Methods：Ten patients with renal glomerular disease received MMF 0.5 g twice a day for three months,then 0.25 g twice a day for three months more,simultaneously,received JinshuiIbao 1.8 g three times a day for six months by oral administration.Before and after the treatment,the alanine aminotransferase（ALT）,serum creatinine（Scr）,WBC,Hb,HBV-DNA,24 h urinary protein and nephridial tissue pathology were detected.Results：Six months later,24 h urinary albumin,Scr HBV-DNA decreased significantly（P〈0.05）,but WBC,Hb,ALT had little change（P〉0.05）.Conclusion：The therapeutic alliance of MMF combined with JinshuiIbao may be a efficient and safe way to renal glomerular disease patients with positive HBV-DNA.